Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07INL
|
|||
| Former ID |
DIB015307
|
|||
| Drug Name |
Ibrexafungerp
|
|||
| Synonyms |
SCY-078
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Vulvovaginal Candidiasis [ICD-11: 1F23.10] | Approved | [1] | |
| Invasive candidiasis [ICD-11: 1F23] | Phase 3 | [2] | ||
| Fungal infection [ICD-11: 1F29-1F2F; ICD-10: B35-B49; ICD-9: 110-118] | Phase 2 | [3] | ||
| Company |
Scynexis
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C44H67N5O4
|
|||
| Canonical SMILES |
CC(C)C(C)C1(CCC2(C3CCC4C5(COCC4(C3=CCC2(C1C(=O)O)C)CC(C5OCC(C)(C(C)(C)C)N)N6C(=NC=N6)C7=CC=NC=C7)C)C)C
|
|||
| InChI |
1S/C44H67N5O4/c1-27(2)28(3)39(7)18-19-41(9)30-12-13-33-40(8)23-52-25-44(33,31(30)14-17-42(41,10)34(39)37(50)51)22-32(35(40)53-24-43(11,45)38(4,5)6)49-36(47-26-48-49)29-15-20-46-21-16-29/h14-16,20-21,26-28,30,32-35H,12-13,17-19,22-25,45H2,1-11H3,(H,50,51)/t28-,30+,32-,33+,34-,35+,39-,40-,41-,42+,43+,44+/m1/s1
|
|||
| InChIKey |
BODYFEUFKHPRCK-ZCZMVWJSSA-N
|
|||
| CAS Number |
CAS 1207753-03-4
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fungal 1,3-beta-glucan synthase (Fung GSC2) | Target Info | Inhibitor | [4] |
| KEGG Pathway | Starch and sucrose metabolism | |||
| MAPK signaling pathway - yeast | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 214900. | |||
| REF 2 | ClinicalTrials.gov (NCT03059992) Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI). U.S. National Institutes of Health. | |||
| REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031918) | |||
| REF 4 | Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model. Antimicrob Agents Chemother. 2015 Feb;59(2):1265-72. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.